O	0	5	Phase
O	6	8	II
O	8	9	,
O	10	20	randomized
O	21	26	trial
O	27	29	to
O	30	37	compare
B-intervention	38	49	anastrozole
I-intervention	50	58	combined
I-intervention	59	63	with
I-intervention	64	73	gefitinib
O	74	76	or
B-control	77	84	placebo
O	85	87	in
O	88	102	postmenopausal
O	103	108	women
O	109	113	with
O	114	121	hormone
O	122	130	receptor
O	130	131	-
O	131	139	positive
O	140	150	metastatic
O	151	157	breast
O	158	164	cancer
O	164	165	.

O	166	170	This
O	171	176	phase
O	177	179	II
O	180	190	randomized
O	191	196	trial
O	197	206	evaluated
O	207	210	the
O	211	219	efficacy
O	220	223	and
O	224	236	tolerability
O	237	239	of
O	240	251	anastrozole
O	252	260	combined
O	261	265	with
O	266	275	gefitinib
O	276	278	or
O	279	290	anastrozole
O	291	295	with
O	296	303	placebo
O	304	306	in
O	307	312	women
O	313	317	with
O	318	325	hormone
O	326	334	receptor
O	334	335	-
O	335	343	positive
O	344	354	metastatic
O	355	361	breast
O	362	368	cancer
O	369	370	(
O	370	373	MBC
O	373	374	)
O	374	375	.

B-eligibility	376	390	Postmenopausal
I-eligibility	391	396	women
I-eligibility	397	401	with
I-eligibility	402	409	hormone
I-eligibility	410	418	receptor
I-eligibility	418	419	-
I-eligibility	419	427	positive
I-eligibility	428	438	measurable
I-eligibility	439	441	or
I-eligibility	442	451	evaluable
I-eligibility	452	455	MBC
I-eligibility	456	459	who
I-eligibility	460	463	had
I-eligibility	464	467	not
I-eligibility	468	476	received
I-eligibility	477	482	prior
I-eligibility	483	492	endocrine
I-eligibility	493	500	therapy
I-eligibility	501	504	for
I-eligibility	505	509	this
I-eligibility	510	517	disease
I-eligibility	518	523	stage
I-eligibility	524	526	or
I-eligibility	527	530	who
I-eligibility	531	540	developed
I-eligibility	541	551	metastatic
I-eligibility	552	559	disease
I-eligibility	560	566	during
I-eligibility	566	567	/
I-eligibility	567	572	after
I-eligibility	573	581	adjuvant
I-eligibility	582	591	tamoxifen
O	592	596	were
O	597	605	eligible
O	605	606	.

O	607	610	The
O	611	618	primary
O	619	627	response
O	628	636	variable
O	637	640	was
B-outcome-Measure	641	652	progression
I-outcome-Measure	652	653	-
I-outcome-Measure	653	657	free
I-outcome-Measure	658	666	survival
I-outcome-Measure	667	668	(
I-outcome-Measure	668	671	PFS
I-outcome-Measure	671	672	)
O	673	676	and
O	677	686	secondary
O	687	695	response
O	696	705	variables
O	706	714	included
B-outcome-Measure	715	723	clinical
I-outcome-Measure	724	731	benefit
I-outcome-Measure	732	736	rate
O	736	737	,
B-outcome-Measure	738	747	objective
I-outcome-Measure	748	756	response
I-outcome-Measure	757	761	rate
O	761	762	,
B-outcome-Measure	763	770	overall
I-outcome-Measure	771	779	survival
O	779	780	,
B-outcome-Measure	781	787	safety
I-outcome-Measure	788	791	and
I-outcome-Measure	792	804	tolerability
O	804	805	,
O	806	809	and
B-outcome-Measure	810	826	pharmacokinetics
O	826	827	.

O	828	833	Tumor
O	834	843	biomarker
O	844	854	evaluation
O	855	858	was
O	859	861	an
O	862	873	exploratory
O	874	883	objective
O	883	884	.

B-intervention-participants	885	890	Forty
I-intervention-participants	890	891	-
I-intervention-participants	891	896	three
O	897	905	patients
O	906	910	were
O	911	921	randomized
O	922	924	to
O	925	936	anastrozole
O	937	941	plus
O	942	951	gefitinib
O	952	955	and
B-control-participants	956	958	50
O	959	967	patients
O	968	972	were
O	973	983	randomized
O	984	986	to
O	987	998	anastrozole
O	999	1003	plus
O	1004	1011	placebo
O	1012	1014	of
O	1015	1016	a
O	1017	1024	planned
O	1025	1030	total
O	1031	1033	of
B-total-participants	1034	1037	174
O	1038	1046	patients
O	1047	1048	(
O	1048	1058	enrollment
O	1059	1062	was
O	1063	1074	prematurely
O	1075	1087	discontinued
O	1088	1091	due
O	1092	1094	to
O	1095	1099	slow
O	1100	1111	recruitment
O	1111	1112	)
O	1112	1113	.

B-outcome	1114	1117	PFS
O	1118	1121	for
O	1122	1130	patients
O	1131	1140	receiving
O	1141	1144	the
O	1145	1156	combination
O	1157	1159	of
O	1160	1171	anastrozole
O	1172	1175	and
O	1176	1185	gefitinib
O	1186	1189	was
O	1190	1196	longer
O	1197	1201	than
O	1202	1205	for
O	1206	1214	patients
O	1215	1224	receiving
O	1225	1236	anastrozole
O	1237	1241	plus
O	1242	1249	placebo
O	1250	1251	[
O	1251	1257	hazard
O	1258	1263	ratio
O	1264	1265	(
O	1265	1274	gefitinib
O	1274	1275	/
O	1275	1282	placebo
O	1282	1283	)
O	1283	1284	,
O	1285	1286	0
O	1286	1287	.
O	1287	1289	55
O	1289	1290	;
O	1291	1293	95
O	1293	1294	%
O	1295	1305	confidence
O	1306	1314	interval
O	1314	1315	,
O	1316	1317	0
O	1317	1318	.
O	1318	1320	32
O	1320	1321	-
O	1321	1322	0
O	1322	1323	.
O	1323	1325	94
O	1325	1326	;
B-outcome	1327	1333	median
I-outcome	1334	1337	PFS
O	1337	1338	,
B-iv-cont-median	1339	1341	14
I-iv-cont-median	1341	1342	.
I-iv-cont-median	1342	1343	7
O	1344	1350	versus
B-cv-cont-median	1351	1352	8
I-cv-cont-median	1352	1353	.
I-cv-cont-median	1353	1354	4
I-cv-cont-median	1355	1361	months
O	1361	1362	]
O	1362	1363	.

O	1364	1367	The
B-outcome	1368	1376	clinical
I-outcome	1377	1384	benefit
I-outcome	1385	1389	rate
O	1390	1393	was
B-iv-bin-percent	1394	1396	49
I-iv-bin-percent	1396	1397	%
O	1398	1404	versus
B-cv-bin-percent	1405	1407	34
I-cv-bin-percent	1407	1408	%
O	1408	1409	,
O	1410	1413	and
O	1414	1417	the
B-outcome	1418	1427	objective
I-outcome	1428	1436	response
I-outcome	1437	1441	rate
O	1442	1445	was
B-iv-bin-percent	1446	1447	2
I-iv-bin-percent	1447	1448	%
O	1449	1455	versus
B-cv-bin-percent	1456	1458	12
I-cv-bin-percent	1458	1459	%
O	1460	1464	with
O	1465	1476	anastrozole
O	1477	1481	plus
O	1482	1491	gefitinib
O	1492	1495	and
O	1496	1507	anastrozole
O	1508	1512	plus
O	1513	1520	placebo
O	1520	1521	,
O	1522	1534	respectively
O	1534	1535	.

O	1536	1538	No
O	1539	1547	evidence
O	1548	1550	of
O	1551	1562	interaction
O	1563	1570	between
O	1571	1579	baseline
O	1580	1589	biomarker
O	1590	1596	levels
O	1597	1600	and
O	1601	1609	relative
O	1610	1619	treatment
O	1620	1626	effect
O	1627	1630	was
O	1631	1636	found
O	1636	1637	.

O	1638	1640	No
O	1641	1651	unexpected
B-outcome	1652	1659	adverse
I-outcome	1660	1666	events
O	1667	1671	were
O	1672	1680	observed
O	1680	1681	.

O	1682	1686	This
O	1687	1692	small
O	1693	1703	randomized
O	1704	1709	study
O	1710	1716	showed
O	1717	1721	that
O	1722	1733	anastrozole
O	1734	1736	in
O	1737	1748	combination
O	1749	1753	with
O	1754	1763	gefitinib
O	1764	1766	is
O	1767	1777	associated
O	1778	1782	with
O	1783	1784	a
O	1785	1791	marked
O	1792	1801	advantage
O	1802	1804	in
O	1805	1808	PFS
O	1809	1817	compared
O	1818	1822	with
O	1823	1834	anastrozole
O	1835	1839	plus
O	1840	1847	placebo
O	1847	1848	,
O	1849	1852	and
O	1853	1857	that
O	1858	1861	the
O	1862	1873	combination
O	1874	1877	was
O	1878	1887	tolerated
O	1888	1890	in
O	1891	1905	postmenopausal
O	1906	1911	women
O	1912	1916	with
O	1917	1924	hormone
O	1925	1933	receptor
O	1933	1934	-
O	1934	1942	positive
O	1943	1946	MBC
O	1946	1947	.

O	1948	1955	Further
O	1956	1969	investigation
O	1970	1972	of
O	1973	1982	epidermal
O	1983	1989	growth
O	1990	1996	factor
O	1997	2005	receptor
O	2006	2016	inhibition
O	2017	2019	in
O	2020	2031	combination
O	2032	2036	with
O	2037	2046	endocrine
O	2047	2054	therapy
O	2055	2058	may
O	2059	2061	be
O	2062	2071	warranted
O	2071	2072	.
